InsiderTrades.com logo
Andrew Combs net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Andrew Combs Biography and Net Worth

EVP of Prelude Therapeutics
Andrew Combs, Ph.D. is the Executive Vice President and Head of Chemistry at Prelude Therapeutics. Dr. Combs joined Prelude in 2019 and has over 23 years of experience as a medicinal chemist. Prior to joining Prelude, Dr. Combs previously held several roles at Incyte Corporation, most recently as Vice President of Discovery Chemistry, where he led teams in medicinal chemistry, analytical chemistry, enabling technologies, computational design, and informatics from 2003 until 2019. Earlier in his career, Dr. Combs held positions of increasing responsibility, starting as a Senior Research Scientist and advancing to a Director of medicinal chemistry at DuPont-Merck, DuPont Pharmaceuticals, and Bristol-Myers Squibb. His passion for research embraces the application of innovative and enabling technologies to expedite the drug discovery process. He has led teams of creative chemists with whom he co-invented >10 clinical candidates, including epacadostat and parsaclisib, which both entered late stage clinical trials in oncology. Dr. Combs holds B.S. degrees in Chemistry and Molecular Biology from the UW-Madison, a Ph.D. in Organic Chemistry from UCLA, and completed his training as a HHMI post-doctoral fellow at Harvard University.

What is Andrew Combs' net worth?

The estimated net worth of Andrew Combs is at least $268,905.34 as of December 23rd, 2024. Dr. Combs owns 377,623 shares of Prelude Therapeutics stock worth more than $268,905 as of March 6th. This net worth evaluation does not reflect any other investments that Dr. Combs may own. Additionally, Dr. Combs receives a salary of $562,460.00 as EVP at Prelude Therapeutics. Learn More about Andrew Combs' net worth.

How old is Andrew Combs?

Dr. Combs is currently 57 years old. There are 4 older executives and no younger executives at Prelude Therapeutics. The oldest executive at Prelude Therapeutics is Dr. Peggy A. Scherle Ph.D., Chief Scientific Officer, who is 62 years old. Learn More on Andrew Combs' age.

What is Andrew Combs' salary?

As the EVP of Prelude Therapeutics Incorporated, Dr. Combs earns $562,460.00 per year. There are 4 executives that earn more than Dr. Combs. The highest earning executive at Prelude Therapeutics is Dr. Krishna Vaddi D.V.M., Ph.D., Founder, CEO & Director, who commands a salary of $905,920.00 per year. Learn More on Andrew Combs' salary.

How do I contact Andrew Combs?

The corporate mailing address for Dr. Combs and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at prelude@argotpartners.com. Learn More on Andrew Combs' contact information.

Has Andrew Combs been buying or selling shares of Prelude Therapeutics?

Andrew Combs has not been actively trading shares of Prelude Therapeutics over the course of the past ninety days. Most recently, on Monday, December 23rd, Andrew Combs bought 60,000 shares of Prelude Therapeutics stock. The stock was acquired at an average cost of $1.37 per share, with a total value of $82,200.00. Following the completion of the transaction, the insider now directly owns 377,623 shares of the company's stock, valued at $517,343.51. Learn More on Andrew Combs' trading history.

Who are Prelude Therapeutics' active insiders?

Prelude Therapeutics' insider roster includes Andrew Combs (EVP), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), and Peggy Scherle (Insider). Learn More on Prelude Therapeutics' active insiders.

Are insiders buying or selling shares of Prelude Therapeutics?

In the last year, Prelude Therapeutics insiders bought shares 5 times. They purchased a total of 198,075 shares worth more than $213,486.25. The most recent insider tranaction occured on December, 30th when CEO Krishna Vaddi bought 10,000 shares worth more than $12,000.00. Insiders at Prelude Therapeutics own 62.8% of the company. Learn More about insider trades at Prelude Therapeutics.

Information on this page was last updated on 12/30/2024.

Andrew Combs Insider Trading History at Prelude Therapeutics

See Full Table

Andrew Combs Buying and Selling Activity at Prelude Therapeutics

This chart shows Andrew Combs's buying and selling at Prelude Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Prelude Therapeutics Company Overview

Prelude Therapeutics logo
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Read More

Today's Range

Now: $0.71
Low: $0.71
High: $0.76

50 Day Range

MA: $1.04
Low: $0.68
High: $1.39

2 Week Range

Now: $0.71
Low: $0.67
High: $6.80

Volume

73,440 shs

Average Volume

240,425 shs

Market Capitalization

$39.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43